Ascendis Pharma A/S

ASND

$13.14B

Large Cap

NASDAQPharmaceutical Preparations🇺🇸EuropeHELLERUP1.0K employees

Website

Drugs in Pipeline

Phase 3 Programs

Upcoming Catalysts

Next Catalyst

Feb 25, 2026

17d

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply

Market Overview

Stock performance and market intelligence

Catalyst Timeline

5 upcoming, 0 past

🎯PDUFANext

FDA PDUFA Date TransCon hGH (standard)

2/25/2026

For pediatric growth hormone deficiency. BLA filing. Extracted from SEC filing: 6-K

Source

Phase 2

Navepegritide Phase 2 Results Expected

March 2026~Navepegritide72

Primary completion for Navepegritide trial (NCT06079398) in Achondroplasia

Source

🎯PDUFA

FDA PDUFA Date TransCon CNP (priority)

4/10/2026

For achondroplasia. BLA filing. Extracted from SEC filing: 6-K

Source

🎯PDUFA

FDA PDUFA Date TransCon hGH (standard)

June 2026~

For pediatric growth hormone deficiency. BLA filing. Extracted from SEC filing: 6-K

Source

Phase 2

Navepegritide Phase 2 Results Expected

December 2026~Navepegritide24

Primary completion for Navepegritide trial (NCT06732895) in Achondroplasia

Source

AI Predictions & Institutional Flow

Machine learning insights and smart money movement

FDA Submissions

Pending NDA/BLA submissions with predicted PDUFA dates

Drug Pipeline

Clinical development programs and drug candidates

Drug Pipeline

Once weekly subcutaneous injection of TransCon hGH

Phase 3

Growth Hormone Deficiency, Pediatric

TransCon CNP

Phase 3

Achondroplasia

Lonapegsomatropin

Phase 3

Growth Hormone Deficiency

TransCon hGH

Phase 3

Growth Hormone Deficiency, Pediatric

TransCon IL-2 β/γ

Phase 2

Advanced Solid Tumor

ACP-001 (TransCon hGH)

Phase 2

Adult Growth Hormone Deficiency

Combination of Navepegritide and Lonapegsomatropin administered as two separate s.c. injections

Phase 2

Achondroplasia

ACP-001

Phase 2

Growth Hormone Deficiency (GHD)

Navepegritide

Phase 2

Achondroplasia

Somatropin

Phase 2

Turner Syndrome

Drug Name	Phase	Indication	Designations
Once weekly subcutaneous injection of TransCon hGH	Phase 3	Growth Hormone Deficiency, Pediatric	-
TransCon CNP	Phase 3	Achondroplasia	-
Lonapegsomatropin	Phase 3	Growth Hormone Deficiency	-
TransCon hGH	Phase 3	Growth Hormone Deficiency, Pediatric	-
TransCon IL-2 β/γ	Phase 2	Advanced Solid Tumor	-
ACP-001 (TransCon hGH)	Phase 2	Adult Growth Hormone Deficiency	-
Combination of Navepegritide and Lonapegsomatropin administered as two separate s.c. injections	Phase 2	Achondroplasia	-
ACP-001	Phase 2	Growth Hormone Deficiency (GHD)	-
Navepegritide	Phase 2	Achondroplasia	-
Somatropin	Phase 2	Turner Syndrome	-

Regulatory & News

Approvals, filings, and latest developments

Regulatory Approvals

ASND News